https://www.selleckchem.com/products/AG-490.html
There was no significant difference in median time to first SRE between the short- and medium-interval denosumab groups [33.2 28.4 months, hazard ratio (HR) 1.13, 95% confidence interval (CI) 0.66-1.92, = 0.91] or the medium- and long-interval dosing groups (28.4 32.2 months, HR 1.15, 95% CI 0.66-2.01, = 0.62). Median OS was not found to differ significantly between any of the groups. There were significantly more hospitalizations in the short-interval dosing group than the other groups (55.2% 33.8% 30.4%, 0.001). Extending denos
Aimer
Commentaire
Partagez
